Merck’s Vioxx Successor Arcoxia May Be Closer To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will need to weigh issues related to hypertension and length of the studies after preliminary results of massive trials show comparable cardiovascular events for etoricoxib and diclofenac.
You may also be interested in...
FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia
FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.
FDA Sets High Bar For Approval Of Merck’s COX-2 Arcoxia
FDA’s Arthritis Drugs Advisory Committee will review Merck’s Vioxx follow-on etoricoxib during an April 12 meeting.
Complete MEDAL Data May Forge Arcoxia Approval
Clinical data presented by Merck is not qualitatively different from preliminary release of trial results for the COX-2 inhibitor.